Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica’s microbiome-based immuno-oncology drug, BMC128
REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ — Bi…